about
Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A.Combination of micellar electrokinetic and high-performance liquid chromatographies to assess age-related changes in the in vitro metabolism of Fischer 344 rat liver.The 'apparent clearance' of free phenytoin in elderly vs. younger adultsAge-related changes in scavenger receptor-mediated endocytosis in rat liver sinusoidal endothelial cellsClinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairmentAge-related pseudocapillarization of the liver sinusoidal endothelium impairs the hepatic clearance of acetaminophen in rats.Age-related changes in the hepatic pharmacology and toxicology of paracetamol.Clinical pharmacology of chemotherapy agents in older people with cancerLiver regeneration and aging: a current perspective.Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration.Age-related loss of hepatic Nrf2 protein homeostasis: Potential role for heightened expression of miR-146a.Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarinPredicted metabolic drug clearance with increasing adult age.Clinical pharmacokinetics of antiretroviral drugs in older persons.Pharmacokinetics and drug metabolism in the elderly.Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.Drug metabolism in older people--a key consideration in achieving optimal outcomes with medicines.Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Alterations in drug disposition in older adults.Impact of renal aging on drug therapy.Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.Anticholinergics: theoretical and clinical overview.Pharmacokinetic and pharmacodynamic alterations in older people with dementia.UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.A unified pharmacokinetic approach to individualized drug dosing.Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery.Delayed awakening after cardiac arrest: prevalence and risk factors in the Parisian registry.Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.The influence of old age and poloxamer-407 on the hepatic disposition of diazepam in the isolated perfused rat liver.Clinical Importance of Monitoring Unbound Valproic Acid Concentration in Patients with Hypoalbuminemia.Pharmacokinetics of intravenous paracetamol in elderly patients.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q30396069-A306648B-76EB-4370-A918-56430AF4E32FQ33957499-77790D92-AD47-4A6F-BA24-DDF4ADE8D1F3Q34019379-F4A69B89-F490-48BC-A7E7-E3BDF0EED2BFQ34062026-C30B2B1A-CD1B-491D-A87D-CD3D2AF6B31EQ34608990-723C75C2-AA82-4C67-9830-250C7BFA0715Q34660298-AB2F4706-B281-460B-A8D5-45D6873F39D8Q35101500-8EE3C918-C12B-4300-A7BF-68F76BB9AB2FQ35159253-D40A9E81-3EDF-4FFC-B2A2-C90A07338CD3Q35207412-38B365C0-165A-4D03-B356-40A5906CC019Q35629807-3AF785CC-50E2-4C0D-8D83-5CB5AAFA8190Q35764910-4A87131D-8EE6-4350-B35A-3C0A81B7ECBCQ36386195-96D5A34B-B517-4C0E-89E9-D706C01FA300Q36390244-D4A1AE2B-0F16-40E1-8A0D-CE6F7C3FDC5EQ36729942-04D4B961-320E-489F-90D4-E4A08906840FQ36905884-3694BA1B-7DD9-4838-B47D-D4E698B56533Q37514319-C52432FC-D244-432E-A118-214445C29CA1Q37660706-41884358-095B-4204-BBBD-4F36F0095FDAQ37915843-9E0979F8-9000-4C08-8257-466AD6E45F57Q38040844-A0C8D9BC-C73A-44EA-9DCE-DB63DCFE46DFQ38103885-0D2D4AB4-1CCD-4FCD-A4E5-5324245B254BQ38323527-A88F2F60-7654-4D31-995C-93EE5BA49756Q38544072-4FA94309-E470-49A3-950F-9CFEA9F0153FQ38627857-7630EE7F-4F9F-4981-9209-B00661205302Q38769800-DA848CA0-2817-42D9-B6A2-82A90B98CC5FQ39275819-333F6979-03ED-4A68-BFCF-32E6910B164DQ39731863-934100B9-6661-4311-B07D-83BD140C1438Q42188074-3ACBD528-84B7-4274-A8CD-8392A97E1BD1Q47306035-D59564A3-4F32-4003-8706-F71B08EC40DEQ47376616-B1879D93-CD75-404A-9BBC-B958B07AA861Q47439082-2BD1C81A-4386-4267-8BAE-BDF243AF7863Q47774021-4FE2D2A7-7D48-4BF3-9202-78A9F6FB46BAQ47853973-9A50AEAF-B05A-4260-8554-9C969DE955F5Q48128637-67BB45D3-1D6A-43B3-8B9F-6AE59AA00A6EQ50962805-A7977A72-B2C8-4DC5-97DA-61A9629FB844Q51516327-8D0F912D-AF40-44B6-96FA-54FB138860E8Q58073610-503A4065-1E99-45B2-BC3C-4A2DDBF868C5
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Free drug metabolic clearance in elderly people.
@ast
Free drug metabolic clearance in elderly people.
@en
Free drug metabolic clearance in elderly people.
@nl
type
label
Free drug metabolic clearance in elderly people.
@ast
Free drug metabolic clearance in elderly people.
@en
Free drug metabolic clearance in elderly people.
@nl
prefLabel
Free drug metabolic clearance in elderly people.
@ast
Free drug metabolic clearance in elderly people.
@en
Free drug metabolic clearance in elderly people.
@nl
P2860
P1476
Free drug metabolic clearance in elderly people
@en
P2093
Evan J Begg
P2860
P304
P356
10.2165/00003088-200847050-00002
P577
2008-01-01T00:00:00Z
P6179
1050196009